Quality of life with cediranib in relapsed ovarian cancer: The ICON6 phase 3 randomized clinical trial. (2017)
Attributed to:
MRC Clinical Trials Unit as the London Hub for Trials Methodology Research
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1002/cncr.30657
PubMed Identifier: 28339098
Publication URI: http://europepmc.org/abstract/MED/28339098
Type: Journal Article/Review
Volume: 123
Parent Publication: Cancer
Issue: 14
ISSN: 0008-543X